@momentumstudy.bsky.social
Thrilled to share that the DESTINATION 2 trial has received the green light for recruitment at The Christie! Looking forward to welcoming patients and making meaningful progress together #clinicaltrials #thechristie #oncologyresearch #prostatecancer
August 4, 2025 at 7:51 AM
Thrilled to share that the DESTINATION 2 trial has received the green light for recruitment at The Christie! Looking forward to welcoming patients and making meaningful progress together #clinicaltrials #thechristie #oncologyresearch #prostatecancer
Reposted
Congratulations to our very own Liz Miles, incredible colleague, mentor & friend on her #ESTRO25 Interdisciplinary Award. A true champion for #collaboration and #RTQA. So well deserved- we could not be prouder!
May 5, 2025 at 1:35 PM
Congratulations to our very own Liz Miles, incredible colleague, mentor & friend on her #ESTRO25 Interdisciplinary Award. A true champion for #collaboration and #RTQA. So well deserved- we could not be prouder!
Reposted
Regional LN delineation variability in #BrCa RT within the Fast Forward trial. Despite this variability, all mandatory constraints were adhered to. #RTQA plays a central role in providing support & guidance to participating centres
www.sciencedirect.com/science/arti...
www.sciencedirect.com/science/arti...
Regional Lymph Node Delineation variability and its Dosimetric Impact in Breast Cancer Radiotherapy
To quantify the interobserver variability of regional lymph node delineation for breast cancer radiotherapy (RT) and establish whether a relationship …
www.sciencedirect.com
April 21, 2025 at 4:46 PM
Regional LN delineation variability in #BrCa RT within the Fast Forward trial. Despite this variability, all mandatory constraints were adhered to. #RTQA plays a central role in providing support & guidance to participating centres
www.sciencedirect.com/science/arti...
www.sciencedirect.com/science/arti...
We are thrilled to announce opening of the ANDROMEDA study! This represents another significant achievement stemming from MOMENTUM infrastructure. We’re excited to leverage our advanced Unity MR-Linac capabilities to deliver dose-escalated adaptive radiotherapy for patients with rectal cancer.
April 2, 2025 at 11:31 AM
We are thrilled to announce opening of the ANDROMEDA study! This represents another significant achievement stemming from MOMENTUM infrastructure. We’re excited to leverage our advanced Unity MR-Linac capabilities to deliver dose-escalated adaptive radiotherapy for patients with rectal cancer.
Happy to announce that the 7000th participant for MOMENTUM has been enrolled at UMC Utrecht yesterday!
March 11, 2025 at 7:37 AM
Happy to announce that the 7000th participant for MOMENTUM has been enrolled at UMC Utrecht yesterday!
Reposted
For muscle-invasive bladder cancer, the Lancet Oncology paper by Zlotta et al is the best comparative effectiveness study of TMT versus RC. How can we use this study to communicate the risks of delayed cystectomy to patients? Peppin A et al provide an answer at GU ASCO 2025:
February 16, 2025 at 6:24 PM
For muscle-invasive bladder cancer, the Lancet Oncology paper by Zlotta et al is the best comparative effectiveness study of TMT versus RC. How can we use this study to communicate the risks of delayed cystectomy to patients? Peppin A et al provide an answer at GU ASCO 2025:
Reposted
Most men with advanced #ProstateCancer benefit from new-generation drugs targeting the androgen receptor (ARPIs), but older patients may benefit from some ARPIs more than others.
These results from the STOPCAP meta-analysis were presented at #ASCOGU25 by @dfishstats.bsky.social.
These results from the STOPCAP meta-analysis were presented at #ASCOGU25 by @dfishstats.bsky.social.
STOPCAP study finds that most men with advanced prostate cancer benefit from new-generation hormone therapy drugs | MRC Clinical Trials Unit at UCL
13 Feb 2025
buff.ly
February 14, 2025 at 9:17 AM
www.phiro.science/article/S240...
Another elegant demonstration of how simplifying complex workflows yields powerful results. By leveraging MOMENTUM's infrastructure, this team shows streamlined adaptive radiotherapy maintains quality while reducing treatment times. Congratulations!
Another elegant demonstration of how simplifying complex workflows yields powerful results. By leveraging MOMENTUM's infrastructure, this team shows streamlined adaptive radiotherapy maintains quality while reducing treatment times. Congratulations!
A simplified online adaptive workflow for long-course magnetic resonance-guided radiotherapy in esophageal cancer
Since the publication of the landmark CROSS trial in 2012 [1], neoadjuvant chemoradiotherapy
has become a cornerstone in the curative treatment of esophageal cancer in much of
the western world. The r...
www.phiro.science
February 11, 2025 at 3:18 PM
www.phiro.science/article/S240...
Another elegant demonstration of how simplifying complex workflows yields powerful results. By leveraging MOMENTUM's infrastructure, this team shows streamlined adaptive radiotherapy maintains quality while reducing treatment times. Congratulations!
Another elegant demonstration of how simplifying complex workflows yields powerful results. By leveraging MOMENTUM's infrastructure, this team shows streamlined adaptive radiotherapy maintains quality while reducing treatment times. Congratulations!